Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2022

Jang J-, Hwang I, Pan H, Yao J, Alinari L, Imada E, et al. A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas. J Clin Invest. 2022;132(24).

C Miller Q, Al-Hader A, Vance GH, Zhang C. Malignant gastrointestinal neuroectodermal tumour arising in the extrahepatic bile ducts; a rare neoplasm in an unusual anatomic location. BMJ Case Rep. 2022;15(7).

Kim J, Rustam S, Mosquera JM, Randell SH, Shaykhiev R, Rendeiro AF, et al. Unsupervised discovery of tissue architecture in multiplexed imaging. Nat Methods. 2022;19(12):1653-1661.

O'Leary MK, Sundaram V, LiPuma JJ, Dörr T, Westblade LF, Alabi CA. Mechanism of Action and Resistance Evasion of an Antimicrobial Oligomer against Multidrug-Resistant Gram-Negative Bacteria. ACS Appl Bio Mater. 2022;5(3):1159-1168.

Bruehl FK, Kim AS, Li MM, Lindeman NI, Moncur JT, Souers RJ, et al. Tiered Somatic Variant Classification Adoption Has Increased Worldwide With Some Practice Differences Based on Location and Institutional Setting. Arch Pathol Lab Med. 2022;146(7):822-832.

Zhang T, Zhang G, Chen X, Chen Z, Tan AY, Lin A, et al. Low-dose carbon monoxide suppresses metastatic progression of disseminated cancer cells. Cancer Lett. 2022;546:215831.

Rodriguez-Flores JL, Messai-Badji R, Robay A, Temanni R, Syed N, Markovic M, et al. The QChip1 knowledgebase and microarray for precision medicine in Qatar. NPJ Genom Med. 2022;7(1):3.

Dias-Santagata D, Heist RS, Bard AZ, Da Silva AF, Dagogo-Jack I, Nardi V, et al. Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network. Oncologist. 2022;27(11):930-939.

Gardner A, Alvarez J, Genovese C, Snodgrass R, Kopparthy V, Erickson D, et al. Simplified detection of Epstein-Barr virus for diagnosis of endemic Burkitt lymphoma. Blood Adv. 2022;6(12):3650-3654.

Temkin SM, Smeltzer MP, Dawkins MD, Boehmer LM, Senter L, Black DR, et al. Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations. Cancer. 2022;128(4):654-664.